ASSET PURCHASE AGREEMENT by and among SALIX PHARMACEUTICALS, INC. SANTARUS, INC., VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L., VALEANT PHARMACEUTICALS NORTH AMERICA LLC, PHARMING GROUP N.V., and PHARMING AMERICAS B.V. Dated as of August 9, 2016Asset Purchase Agreement • December 17th, 2020 • Pharming Group N.V. • Pharmaceutical preparations
This ASSET PURCHASE AGREEMENT (this “Agreement”), is made as of August 9, 2016, by and among Salix Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of California (“Salix”), Santarus, Inc., a corporation duly organized and existing under the laws of the State of Delaware (“Santarus”), Valeant Pharmaceuticals Luxembourg S.à r.l., a société à responsibilité limitée (private limited liability company) duly formed and validly existing under the laws of the Grand Duchy of Luxembourg (“VPL”), Valeant Pharmaceuticals North America LLC, a limited liability company duly formed and validly existing under the laws of the State of Delaware (together with Salix, Santarus and VPL, the “Sellers,” and each a “Seller”), Pharming Group N.V., a corporation duly organized and existing under the laws of the Netherlands (“NV Purchaser”) and Pharming Americas B.V. a private limited liability company duly organized and existing under the laws of the Netherlands (“Pha
